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Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyeli-
nation and neurodegeneration in the central nervous system. Until recently, disease-
modifying treatment was based on agents requiring parenteral delivery, thus limiting
long-term compliance. Basic treatments such as beta-interferon provide only moderate
efficacy, and although therapies for second-line treatment and highly active MS are more
effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is
the first oral treatment of MS and has recently been approved as single disease-modifying
therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients
with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve
patients with rapidly evolving severe RRMS. At a scientific meeting that took place in
Vienna on November 18th, 2011, experts from ten Central and Eastern European countries
discussed the clinical benefits and potential risks of fingolimod for MS, suggested how
the new therapy fits within the current treatment algorithm and provided expert opinion
for the selection and management of patients.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic, immune-mediated disease of
the central nervous system (CNS) in which autoreactive CD4+ and
CD8+ T lymphocytes, B lymphocytes, macrophages, antibodies,
and cytokines attack the myelin sheaths and damage the axons.
MS appears in distinct disease courses, the most common of which
shows a waxing and waning of neurological symptoms and signs,
and is thus termed relapsing-remitting MS.
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The standard disease-modifying drugs (DMDs) such as
interferon-beta and glatiramer acetate provide moderate efficacy
and a low to moderate frequency of side effects. Second-line
therapies for highly active MS such as the humanized antibody
natalizumab and the cytostatic agent mitoxantrone are more effec-
tive, but associated with potentially severe side effects [e.g., pro-
gressive multifocal leukoencephalopathy (PML), cardiotoxicity,
acute leukemia]. All these currently available treatments for
MS require regular and frequent parenteral administration and
may therefore interfere with long-term compliance. Fingolimod
(Gilenya®) is the first oral treatment of MS with a completely new
mode of action targeting not only inflammation but potentially
also neurodegeneration. It has recently been approved as sin-
gle disease-modifying therapy in highly active relapsing-remitting
MS (RRMS) for adult patients with high disease activity despite
basic treatment (beta-interferon) and for treatment-naïve patients
with rapidly evolving severe RRMS. The approval was based on
the largest phase III clinical trial program in MS at the time of
submission.
The increasing information on the pathophysiology of both ini-
tial and later stages of the disease and the fact that tissue damage
is irreversible mean that an early start to an effective therapy is the
only way to obtain good results in the treatment of MS. It has to be
taken into account that only 30% of MS patients are full respon-
ders to first-line treatment and also that the risk/benefit ratio
changes with the severity of the disease. Furthermore, at least 30%
of patients receiving immunomodulatory treatment have at least
one relapse per year and disease activity as shown by MRI indi-
cates that a switch to another medication could be helpful (Mäurer
et al., 2011). Often, the exposure to ineffective first-line drugs
is unacceptably long. Therefore a decision not to escalate early
for economic reasons may be wrong and short-sighted because
disability is incrementally expensive. For a reasonable therapy
algorithm clinical evidence as well as considerations about the
individual benefit/risk-balance, the patient’s wishes, and last but
not least also economic aspects have to be taken into account.
At a scientific meeting that took place in Vienna on Novem-
ber 18th, 2011, experts from ten Central and Eastern European
countries discussed the clinical benefits and potential risks of fin-
golimod for MS, suggested how the new therapy fits within the cur-
rent treatment algorithm (Figure 1 modified from Fazekas, 2012)
and gave recommendations for the selection and management
of patients. In many instances these reflect meeting participants’
expert opinions due to the lack of scientific evidence in several
issues at this stage.
INDICATION
Whereas fingolimod is approved as first-line medication in the
USA, in Switzerland, and in Australia, Europe has a more
conservative approach. Here fingolimod is indicated and labeled
as single disease-modifying monotherapy in highly active RRMS
for the following adult patient groups (EU wide marketing
authorization for Gilenya® granted on 17 March 2011):
• Patients with high disease activity despite treatment with a beta-
interferon. These patients may be defined as those who have
failed to respond to a full adequate course (normally at least
1 year of treatment) of beta-interferon. Patients should have
had at least one relapse in the previous year while on therapy,
and have at least nine T2 hyperintensive lesions on cranial
MRI, or at least one Gadolinium-enhancing lesion. A “non-
responder”could also be defined as a patient with an unchanged
FIGURE 1 | Current options of escalating immunotherapy for RRMS.
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FIGURE 2 | Fingolimod identification and selection of patients.
or increased relapse rate or ongoing severe relapses, as compared
to the previous year (Figure 2).
• Patients with rapidly evolving severe RRMS without prior treat-
ment, defined by two or more disabling relapses in 1 year, and
with one or more Gadolinium-enhancing lesions on brain MRI
or a significant increase in T2 lesion load as compared to a recent
MRI.
• From a clinical point of view treatment failure is defined as
continuing disease activity (in the form of relapses supported
by new or active MRI lesions) and progression in disability.
• According to expert opinion these definitions would similarly
apply to prior treatment with glatiramer acetate.
In clinical practice unbearable side effects and low compliance may
be considered as another kind of treatment failure.
MODE OF ACTION
Fingolimod is the first-in-class sphingosine 1-phosphate receptor
(S1PR) modulator that binds with different affinities to four of the
five known receptors (S1P1, S1P3, S1P4, and S1P5). S1P has impor-
tant functions in the immune system, CNS and cardiovascular
system, and S1P signaling plays a key role in neuroinflammatory
processes (Spiegel and Milstien, 2003; Brinkmann, 2007, 2009;
Rivera et al., 2008; Aktas et al., 2010).
The binding of fingolimod-P to the receptor is followed by the
internalization and degradation of the receptor-fingolimod com-
plex resulting in a secondary loss of surface receptors. As a result
an initial agonist activity turns into a functionally antagonistic
pharmacological effect during long-term administration (Chun
and Brinkmann, 2011).
Fingolimod’s main effect on the immune system is the down-
modulation of S1P1 receptors in lymphocytes, which leads
to a reversible retention of circulating lymphocytes in lymph
nodes, reducing their recirculation to the CNS. Fingolimod selec-
tively inhibits naïve and central memory T-cell egress from
lymph nodes but spares effector memory T-cells (p< 0.005
vs. untreated patients; Mehling et al., 2008) and retains their
functional capacity (Mehling et al., 2008, 2010) and therefore pre-
serves key immune functions (defense against infection; Pham
et al., 2008; Brinkmann, 2009; Chun and Hartung, 2010). It
causes a redistribution, rather than depletion, reducing the
infiltration of autoreactive lymphocytes into the CNS where
they would be involved in inflammation and nervous tissue
damage.
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Table 1 | Immunomodulatory properties of fingolimod.
The available data support the notion that fingolimod at its approved dose may not act as a potent immunosuppressant
Neuroprotective CNS effects unrelated to immunosuppression may be present
Suboptimal prevention of graft rejection was achieved in renal transplantation studies in combination with cyclosporine, despite being at 10× the
approved MS dose
Immunological constituents are maintained (cellular and humoral), with reversible effects on cell location of some (but not all) lymphocyte
subsets – without inhibition of proliferation, differentiation, and cytotoxicity
Immunological surveillance is maintained through relatively unaffected effector memory T-cells
Clinically, the overall incidence of infections as well as of serious and severe infections is not substantially increased
Modified from Chun and Brinkmann (2011).
The different receptor binding explains why fingolimod has dif-
ferent pharmacodynamic properties from the classical immuno-
suppressants and is, thus, defined as a selective immunosuppres-
sant (Table 1). It does not appear to inhibit the activation, pro-
liferation, or memory formation of T-cells, nor to interfere with
antibody formation by B cells, and cytokine synthesis by T-cells.
Based on its lipophilic nature fingolimod crosses the blood-
brain barrier and the oral formulation can result in biologically
active concentrations in the CNS (Foster et al., 2007).
There is a growing body of preclinical evidence to indicate
that the drug also down-modulates S1P1 in CNS cells, e.g.,
astrocytes to reduce astrogliosis, a phenomenon associated with
neurodegeneration in MS. This may help restore gap-junctional
communication of astrocytes with neurons and cells of the blood-
brain barrier. Additional effects may result from (down-) mod-
ulation of S1P3 in astrocytes and of S1P1 and S1P5 in oligoden-
drocytes. Thus, fingolimod may target the disease process of MS
not only by reducing inflammation, but also by direct protective
actions within the lesions.
CLINICAL DATA: FINGOLIMOD IN RRMS
EFFICACY
Two recent multinational phase III studies in RRMS, the TRANS-
FORMS (Cohen et al., 2010a), and FREEDOMS (Kappos et al.,
2010) studies, compared fingolimod with interferon-beta-1a (IFN
beta-1a), or placebo, respectively, with both demonstrating supe-
rior efficacy in terms of clinical and MRI outcomes.
Fingolimod treatment significantly reduced annualized relapse
rate (ARR) vs. control in both studies (p< 0.001). In the TRANS-
FORMS study (n= 1292 patients) the relative reduction in ARR
was 52% vs. IFN beta-1a at 1 year (Figure 3). About 83% of
fingolimod-treated patients remained relapse-free, compared with
69% receiving IFN beta-1a (p< 0.001). In the FREEDOMS study
(n= 1272) the relative reduction in ARR was 54% compared with
placebo (Figure 4). After 2 years of therapy, 70% of the patients in
the fingolimod group remained free from relapses (vs. 46% in the
placebo group). Fingolimod 0.5 mg reduced the risk of disability
progression confirmed after 3 and 6 months by 30% (p= 0.02)
and 37% (p= 0.01), respectively, compared with placebo over
2 years. Patients who received IFN beta-1a in the TRANSFORMS
study (months 0–12) had a significant reduction in ARR within
1 year of switching to fingolimod (months 13–24;−30%, p< 0.05;
Cohen et al., 2010b). However, patients receiving fingolimod for
2 years continuously had an even greater reduction in ARR than
patients receiving IFN beta-1a for 1 year before switching to fin-
golimod for the second year [ARR (95% CI) 0.33 (0.27–0.39) vs.
0.18 (0.14–0.22); relative risk reduction:−46%; p< 0.001].
During the FREEDOMS study EDSS scores remained stable,
compared with baseline, in patients receiving fingolimod treat-
ment (mean EDSS score± SD, 0.0± 0.88) and worsened in the
placebo group (0.13± 0.94; p= 0.002). Similarly, MS Functional
Composite (MSFC) z-scores improved slightly in patients receiv-
ing fingolimod (0.03± 0.39), compared with baseline, and wors-
ened in the placebo group (−0.06± 0.57; p= 0.01).
Subgroup analyses showed that fingolimod treatment had con-
sistent effects, regardless of whether patients were treatment-
naïve or had previously received disease-modifying therapy, and
irrespective of gender, pre baseline disease activity, or disease
history (Devonshire et al., 2012). Recent post hoc analyses from
FREEDOMS and TRANSFORMS demonstrated that fingolimod
is an effective treatment in treatment-naïve patients with severe
disease (rapidly evolving severe RRMS defined as ≥2 relapses in
the previous year and≥1 Gd+ lesion at baseline). The ARR reduc-
tion was 67% at 2 years compared with placebo (p< 0.001) and
25% at 1 year compared with IFNβ-1a (p= 0.614; Havrdová et al.,
2011; Devonshire et al., 2012).
EFFECT ON MRI MEASURES
Fingolimod therapy demonstrated a highly significant reduction
in inflammatory disease activity (T1 Gd-enhancement, new, or
enlarging T2-lesions), burden of disease (volume of T2/PD hyper-
intensive lesions), and tissue loss and destruction [volume of T1
hypointense lesions (black holes)].
Fingolimod 0.5 mg significantly (p< 0.001) reduced the num-
ber of MRI inflammatory lesions vs. placebo (Kappos et al., 2010).
After 2 years the relative reduction was 74% for new or enlarged
T2-lesions (2.5 vs. 9.8) and 82% for Gd-enhancing T1 lesions
(0.2 vs. 1.1). Patients treated with fingolimod 0.5 mg also had
significantly fewer new or enlarged hyperintense lesions on T2
weighted images (1.7 vs. 2.6 for IFN beta-1a, RR= 35%) and fewer
Gd-enhancing T1 lesions (0.23 vs. 0.51, RR= 55%) at 12 months
compared to the IFN beta-1a group (Cohen et al., 2010a).
Patients who switched to fingolimod after receiving IFN beta-1a
had further significant reductions in inflammatory lesion activity
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FIGURE 3 | Adjusted annualized relapse rate in theTRANSFORMS study comparing the efficacy of fingolimod with interferon-beta-1a i.m.
FIGURE 4 | Adjusted annualized relapse rate in the FREEDOMS study comparing the efficacy of fingolimod with placebo.
(Cohen et al., 2010b). The relative risk reduction was 66% for
new or enlarged T2-lesions (2.1 for IFN beta-1a vs. 0.7 for fin-
golimod 0.5 mg; p< 0.001 for year 1 vs. year 2) and as much as
80% for Gd-enhancing T1 lesions (0.5 vs. 0.1; p< 0.002). Long-
term phase II-data showed that these effects were sustained and
did not diminish with long-term treatment (Antel et al., 2012).
Fingolimod treatment also resulted in a significant decrease
in total lesion volumes with a relative reduction of 83% for T1
hypointense “black hole” lesion volume compared with placebo
after 2 years (8.8 vs. 50.7%; p= 0.012). The relative reduction of
T2 lesion volume (burden of disease) was 69% (10.6 vs. 33.8%;
Cohen et al., 2010a; Radue et al., 2010).
Brain volume data from MS clinical studies support the effi-
cacy of fingolimod in preventing brain damage (Brinkmann,
2007). This effect was seen as early as Month 6 and was sus-
tained until study end, independent of the inflammation status,
resulting in a 38% reduction in the rate of brain volume loss with
fingolimod 0.5 mg compared with placebo (p< 0.001; Figure 5;
Radue et al., 2010). The brain volume data in FREEDOMS I were
confirmed in FREEDOMS II (Kappos et al., 2012). Moreover,
fingolimod led to a stronger reduction in the rate of brain atro-
phy over 1 year when compared to IFN beta-1a, irrespective of
prior disease activity (Barkhof et al., 2011; Devonshire et al.,
2012).
TOLERABILITY
The phase III studies reported similar fingolimod-related adverse
events (AEs). These included transient, dose-dependent, generally
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FIGURE 5 | Brain volume data in the FREEDOMS study comparing the efficacy of fingolimod with placebo.
asymptomatic cardiac events with the first dose, mild blood pres-
sure increases, rare macular edema and asymptomatic, reversible
elevation of liver enzymes (Figure 6). All observed side effects
are well explained by the S1P-receptor binding properties of
fingolimod.
During treatment with fingolimod lymphocyte counts dropped
rapidly within 4–6 h, approaching steady state levels in 2–4 weeks,
and remained stable on continued treatment (Figure 7). Fin-
golimod leads to selective and reversible redistribution of lym-
phocytes without causing any lymphocytotoxicity. Lymphocytes
are retained in the lymph nodes and are not destroyed (Francis
et al., 2011). The lymphocyte function is maintained. A recovery
to normal levels usually takes place within 1–3 months. Despite
the reduction in lymphocyte counts, fingolimod-treated patients
with MS were shown not to have more infections apart from a
somewhat higher number of respiratory tract infections (Kap-
pos et al., 2012) and were able to mount antigen-specific immune
responses in vaccination studies (Kappos et al.,2011; Mehling et al.,
2011).
MANAGING FINGOLIMOD IN CLINICAL PRACTICE
Fingolimod has been available in the EU since March 2011 and
can be easily transferred from the extensive MS clinical study
program to clinical practice. Four steps are considered essential
for treating patients with fingolimod. The first step and proba-
bly the most important issue is the identification and selection of
patients.
IDENTIFICATION AND SELECTION OF PATIENTS
Non-responder to IFN beta or glatiramer acetate (GA)
Switching to an escalation therapy with either fingolimod or
natalizumab is indicated for patients with high disease activity
despite treatment with IFN beta or GA. Non-responders should
have at least one relapse in the previous year while on therapy, and
have at least 9 T2 hyperintense lesions in cranial MRT or at least
one Gd-enhancing lesions (Figure 8).
Some additional considerations to these definitions should
probably be taken into account. For patients who have had no
relapse and no marked progression in the MRI for some years
before developing a single mild relapse switching to an escalation
therapy might not be immediately mandatory. These patients
would fulfill the criteria, but it is questionable whether a sin-
gle mild relapse should be assessed as definite disease progres-
sion. These patients should probably be re-evaluated within the
next 3–6 months and an escalating therapy should be consid-
ered only upon further overt inflammatory disease activity. On
the other hand an earlier treatment escalation could be consid-
ered for clinically isolated syndrome patients with 9 T2-lesions or
one Gd-enhancing lesion developing a relapse within 1 year, even
though these patients would not fulfill the criteria of at least one
relapse. A relapse within such a short period might be a potential
sign of active disease and could be associated with a very poor
prognosis.
In the clinical management it should also be considered to test
for neutralizing antibodies against IFN beta to become aware of
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FIGURE 6 | Adverse event profile comparing the efficacy of fingolimod with interferon beta-1a i.m.
probable treatment failure and to consider spinal MRI in addition
to brain MRI for estimating disease severity and prognosis.
In principal, treatment modification should be considered with
any deterioration or evidence for new disease activity. Switching
from one basic treatment to another does not appear advisable due
to the risk of further insufficient benefit although in some individ-
ual cases patients might benefit from this strategy. In general, how-
ever, the only useful option is a treatment escalation either with
fingolimod or natalizumab, the choice of which will depend on the
individual circumstances, including contraindications (Table 2)
and the patient’s preferences.
As a next step testing of anti-JCV antibodies is recommended.
This test is available free of charge at present. In anti-JCV antibody
positive patients the first choice could be fingolimod, but nata-
lizumab could also be considered. However, it should be kept in
mind that the risk of developing PML increases after a natalizumab
treatment duration of 2 years and especially in patients pre-treated
with immunosuppressants. In anti-JCV antibody negative patients
fingolimod and natalizumab appear to be similar options, but due
to the longer clinical experience with natalizumab, which has been
approved since 2006, at the moment this drug could be considered
to be the first choice for 2 years of treatment.
Currently there is no evidence about a permanent or resid-
ual effect on the immune function of fingolimod in the long-
term of discontinuation (for prolonged immune reconstitution:
see Johnson et al., 2010). In fact in the majority of patients
lymphocyte counts return to basal levels most likely result-
ing in a complete functional restitution within a period of
3 months after cessation of fingolimod. Although patients’ JCV
stages could be taken into account when making decisions about
escalation therapy following interferons, there is currently no
evidence that the risk of PML would be increased in JCV
antibody positive patients receiving fingolimod treatment. In
contrast the relation between JCV status and risk has been
widely described for natalizumab treatment (Bloomgren et al.,
2012).
Therapy-naïve patients
According to the EU-label, in treatment-naïve patients with rapidly
evolving severe RRMS, defined by one or more disabling relapses
in 1 year, and with one or more Gd-enhancing lesions on brain
MRI, or a significant increase in T2 lesion load as compared
to a previous recent MRI, treatment with fingolimod as well as
natalizumab is indicated (Figure 9). The first step is to inform
the patient about treatment options and consider the benefit/risk-
balance. As a second step all contraindications for both treatment
options have to be assessed. In the presence of recurrent infections,
e.g., herpetic infections, a preventive treatment with acyclovir can
be combined with both of these drugs. Mild hepatic impairment
is not a contraindication for fingolimod, but requires a careful
and frequent (3 monthly) monitoring of liver enzymes (transami-
nases). The rationale for starting with fingolimod or natalizumab
is that only 30% of patients respond to first-line standard treat-
ment and particularly patients with an early and rapidly evolv-
ing RRMS may have a bad prognosis if they are not adequately
treated from the beginning. Furthermore fingolimod has demon-
strated a 25% reduction in ARR vs. IFN beta-1a (p= 0.614) in
treatment-naïve patients with severe disease at 1 year (Devonshire
et al., 2012). The only other alternative would be an unspecific
immunosuppressive drug, and this would complicate all other
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FIGURE 7 | Effects of fingolimod on lymphocyte counts and distribution after discontinuation (disc).
treatment options afterward. A recently completed pharmacoeco-
nomics study showed that even in poor economic countries dis-
ability is three times more expensive than the treatment cost
(Blahova-Dusankova et al., 2012). This might also be a strong
argument for a more expensive, but also more effective ther-
apy from the very onset of highly active disease in this patient
group.
Switch from natalizumab to fingolimod
In a hierarchy of the approved treatments for RRMS fingolimod
and natalizumab are equally positioned in Europe. In anti-JCV
antibody positive patients with a treatment duration≥ 2 years and
prior immunosuppression a termination of natalizumab treat-
ment is recommended due to the high risk of developing PML
(Figure 10). Other reasons that might constitute an indication for
switching from natalizumab are persisting neutralizing antibod-
ies against natalizumab, side effects and poor compliance, and also
ongoing disease activity (Figure 11). Just one mild symptom alone
is not necessarily a reason to terminate natalizumab treatment
and supportive evidence from MRI should be used for further
treatment decisions.
A switch to fingolimod appears favorable over first-line DMDs
for various reasons: as natalizumab is indicated as a second-line
treatment, it can be assumed that the patient has received prior
basic treatment and is a non-responder to these drugs. Therefore
it is unlikely that the patient would like to return to basic treatment
and would benefit from it. In line with this are the data from the
RESTORE trial (Fox et al., 2011). In this study, all patients were
treated for more than 1 year and were relapse-free before treat-
ment with natalizumab was interrupted for 24 weeks. The patients
were randomized to continue natalizumab treatment or stop natal-
izumab and receive either methylprednisolone, intramuscular IFN
beta-1a, or subcutaneous GA for up to 28 weeks, followed by re-
initiation of natalizumab. MRI scans showed increasing disease
activity 12 weeks after stopping natalizumab therapy. Further, 44%
of patients on placebo, 53% on GA, 40% on methylprednisolone,
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FIGURE 8 |Treatment algorithm for non-responders to interferon-beta or glatiramer acetate.
Table 2 | Contraindications.
FINGOLIMOD
Known immunodeficiency syndrome
Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving
immunosuppressive therapies or those immunocompromised by prior therapies)
Severe active infections, active chronic infections (hepatitis, tuberculosis)
Known active malignancies, except for patients with cutaneous basal cell carcinoma
Severe liver impairment (Child-Pugh class C)
Hypersensitivity to the active substance or to any of the excipients
Some cardiac disorders especially when requiring antiarrhythmic treatment
NATALIZUMAB
Hypersensitivity to natalizumab or to any of the excipients
PML, increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive
therapies or those immunocompromised by prior therapies, e.g., mitoxantrone or cyclophosphamide)
Combination with beta-interferons or glatiramer acetate
Known active malignancies, except for patients with cutaneous basal cell carcinoma
Children and adolescents below the age of 18 years
and 7% on IFN beta-1a required rescue treatment consisting of
high-dose corticosteroids or restarting natalizumab.
Therefore in the vast majority of patients a switch to fingolimod
is recommended. First experiences after switching demonstrated
that fingolimod is effective in reducing re-occurrence of disease
activity after natalizumab discontinuation and causes no severe
AEs (Havla et al., 2011).
Wash out period. Generally after termination of the treatment
with IFN beta or GA no wash out period is necessary, if blood count
and liver function are normal. After prior immunosuppressive
treatment a wash out period of 6 months is recommended in the
summary of product characteristics (SPC).
After natalizumab the label recommends a treatment-free inter-
val of 3 months. As discussed above disease activity begins to
return within 3 months after natalizumab treatment interruption
(O’Connor et al., 2011). ARRs and Gd+ lesions both increased
shortly after interruption and peaked between 4 and 7 months. The
extent to which disease activity recurs depends largely on activity
before initiation of any disease-modifying treatment together with
disease activity before starting natalizumab. It is assumed that a
switch from natalizumab to fingolimod is being considered based
on clinical need, i.e., to treat patients with otherwise very active
disease. Therefore particularly in patients with high disease activity
before natalizumab treatment and insufficient treatment response
an early switch to fingolimod is recommended. The main goal is
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FIGURE 9 | Algorithm for treatment-naïve patients.
FIGURE 10 | Risk estimation for progressive multifocal leukoencephalopathy (PML) for patients on natalizumab.
to avoid the patient falling into a gap where natalizumab is not
active anymore and fingolimod is not yet active. At present we
lack specific tests to predict this situation and have to depend on
clinical observations. Furthermore, we have to wait for more data
informing us whether and to what extent the risk of developing
PML is prolonged after termination of natalizumab treatment.
A risk of PML with fingolimod itself is unlikely. In clinical tri-
als overall 4000 patients have been treated with fingolimod for a
mean duration of 2.5 years, and 140 of them are in the seventh
year of treatment. At an average incidence rate of 1.0 PML-case
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FIGURE 11 | Reasons that might constitute an indication for switching from natalizumab to fingolimod.
in 1000 patients (based on the natalizumab figures) there should
have been at least two PML-cases to date, but so far no cases have
been identified under fingolimod treatment without prior, recent
natalizumab exposure. Furthermore, at the moment there is no
clinical evidence of immunosuppression (all patients had normal
differential white blood count).
PREPARATORY STEPS
Before starting fingolimod some preparatory steps have to be
taken, which include:
• Detailed information to the patient about mode of action, fre-
quent AEs, contraception, infections, participation in regular
checkups, and management plan information to the GP
• Check of disease activity: recent MRI should be available or
performed
• History of concomitant diseases and treatments (e.g., antiar-
rhythmic drugs)
• Neurostatus and physical examination: in the case of relevant
findings referral to a specialist (e.g., cardiologist, ophthalmol-
ogist); ECG if positive cardiological findings in history or
examination
• Lab testing: hematology incl. absolute lymphocyte count (lym-
phocyte subpopulations); serology incl. liver enzymes, varicella-
zoster virus (VZV) titer
• If patient is female: pregnancy test and information of patient
about strict and effective contraception
• Depending on individual pre-treatment, appropriate washout
period (not applicable for basic immunomodulatory
medications).
OBSERVATION PERIOD
After evaluation of the preparatory steps fingolimod treatment
can be initiated. After an unexplained sudden death of a patient
within 24 h after taking the first dose of fingolimod has occurred
an extensive re-evaluation of the clinical data on fingolimod has
been performed by the US and also the European health agen-
cies (Fazekas, 2012). New recommendations have therefore been
made. All patients starting treatment should be observed clinically
for a period of at least 6 h for symptoms and signs of bradycardia,
AV-block, and hypertension following the initial administration
of the drug. This 6 h period can also be used for patient education
and explanation of the fingolimod management plan by the MS
manager.
Monitoring during the first 6 h after dosing should include
(according to the CHMP recommendations)1:
• A 12-lead ECG and blood pressure measurement before starting
the first dose and after 6 h
• Blood pressure and heart rate measurement every hour after the
first dose for 6 h
1The full version of recommendations can be read in the SPC.
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FIGURE 12 | Recommended patient management plan for treatment with fingolimod.
• During the first 6 h of treatment continuous real time ECG
monitoring is recommended.
The patient is discharged after 6 h if the heart rate is unchanged
or no longer decreasing. If the patient’s heart rate at the end of
the 6 h period is the lowest following first dose administration, the
monitoring should be extended by at least 2 h, and until the heart
rate increases again.
In those patients with evidence of clinically important car-
diological side effects during the first 6 h, monitoring should
be extended, including at least overnight monitoring, until
resolution.
PATIENT MANAGEMENT PLAN
According to the risk management plan (Figure 12) the first
visit in the long-term follow-up is 1 month after the start of fin-
golimod treatment and includes laboratory testing (hematology
incl. absolute lymphocyte counts, liver enzymes), neurological
and physical examination, and history, information to the patient,
and assessment of vital signs (blood pressure, heart rate). The
second visit after 3 months includes the same examinations and
an additional ophthalmological examination to exclude macu-
lar edema. The management plan entails subsequent visits every
3 months (laboratory testing, neurological and physical examina-
tion, history, and vital signs). Women of childbearing potential
must be advised on the potential serious risk for the fetus and
the need for effective contraception during treatment with fin-
golimod, prolonged for about 2 months after treatment termi-
nation. If a woman becomes pregnant while on treatment with
fingolimod, discontinuation of treatment is recommended. Fur-
thermore, every woman of childbearing potential who receives
treatment with fingolimod should be added to the multinational
Gilenya® Pregnancy Registry.
Finally, we have to note that the management plan for fin-
golimod treatment as presented here has been discussed by MS
experts exclusively from countries where the indication for fin-
golimod is “highly active disease.” It was not the aim of the
expert meeting and therefore the aim of this paper to apply
the introduced criteria also in countries where fingolimod has
a first-line indication. Physicians from countries with a first-
line indication of fingolimod are therefore recommended to
apply criteria that have been developed for their respective
regions.
FUTURE PERSPECTIVES
Further long-term experience and the large ongoing and planned
study program will deliver more clinical evidence and help us to
define the increasingly exact position of the new therapy within
our therapeutic armamentarium.
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